View Older Stories View More Recent Stories

Sep 15, 2016 08:31AM Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Sep 13, 2016 09:00AM Merck Publishes 2015/2016 Global Corporate Responsibility Report
Sep 9, 2016 08:00AM Merck to Participate at the Morgan Stanley Global Healthcare Conference
Sep 7, 2016 06:49AM Merck (MRK) Announces FDA Accepts BLA with Priority Review and Grants Breakthrough Therapy Designation for KEYTRUDA for NSCLC
Sep 7, 2016 06:48AM Merck's (MRK) KEYTRUDA sBLA in NSCLC Accepted for FDA Priority Review
Sep 7, 2016 06:45AM FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients
Sep 2, 2016 07:01AM Merck (MRK) to Discontinue Development of Odanacatib for Osteoporosis
Sep 2, 2016 07:00AM Merck Provides Update on Odanacatib Development Program
Aug 8, 2016 05:06PM Merck (MRK) Announces Publication of Strong ZEPATIER Phase 3 Data as HCV Treatment
Aug 8, 2016 05:05PM Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Me
Aug 8, 2016 06:45AM REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemot
Aug 8, 2016 06:22AM Merck (MRK) Announces FDA Approval of KEYTRUDA as HNSCC Treatment
Aug 5, 2016 07:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Aug 5, 2016 08:04AM Merck (MRK) Announces FDA Filing Acceptance of NDA for MK-1293
Aug 5, 2016 08:00AM Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
Aug 2, 2016 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Jul 29, 2016 06:45AM Merck Announces Second-Quarter 2016 Financial Results
Jul 26, 2016 12:50PM Merck Announces Fourth-Quarter 2016 Dividend
Jul 25, 2016 08:00AM Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
Jul 22, 2016 07:02AM Merck (MRK) Reports Statistically non-Inferior Data from ISENTRESS Phase 3 in HIV-1
Jul 22, 2016 07:00AM Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
Jul 21, 2016 05:02PM Merck (MRK) Animal Health Announces FDA Approval of BRAVECTO
Jul 21, 2016 05:00PM Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs
Jul 21, 2016 04:33PM Merck (MRK) Provides Regulatory Update on BLA for Bezlotoxumab; Says FDA Requested Submission of New Data and Analyses from MODIFY Trials
Jul 21, 2016 04:30PM Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
Jul 6, 2016 08:02AM Pfizer (PFE), Merck (MRK) Commence Aveluma Combo Phase 3 in Ovarian Cancer
Jul 1, 2016 12:07PM Merck Animal Health to Acquire Controlling Vallée S.A. Stake in $400M Deal (MRK)
Jul 1, 2016 12:05PM Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.
Jun 30, 2016 08:31AM Premier (PINC), Merck (MRK) Enter Osteoporosis-Focused Collaboration
Jun 30, 2016 08:31AM Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients
Jun 29, 2016 07:00AM Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
Jun 27, 2016 06:28AM Merck (MRK) Announces Receipt of Positive CHMP Opinion on KEYTRUDA as NSCLC Treatment
Jun 27, 2016 06:00AM Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Jun 24, 2016 08:00AM Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
Jun 22, 2016 04:36PM Incyte (INCY) Treats First Patient in ECHO-301 Combo Phase 3 (MRK)
Jun 20, 2016 12:35PM Merck (MRK) Announces Relebactam Combo Phase 2 Met Primary Endpoint
Jun 20, 2016 12:30PM Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Jun 16, 2016 08:00AM Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
Jun 16, 2016 06:46AM Merck (MRK) Announces Superior Data on KEYTRUDA vs. Chemotherapy in Untreated NSCLC
Jun 16, 2016 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Jun 15, 2016 08:30AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
Jun 13, 2016 10:31AM Merck (MRK) Announces MK-1293 Met Primary Endpoint in Two Phase 3 Studies
Jun 13, 2016 10:30AM Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Jun 11, 2016 11:00AM Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
Jun 9, 2016 06:34PM Merck to Acquire Afferent Pharmaceuticals
Jun 9, 2016 05:08PM Merck (MRK) Enters Agreement to Acquire Afferent Pharma in ~$1.25B Deal
Jun 9, 2016 05:07PM Merck to Acquire Afferent Pharmaceuticals
Jun 6, 2016 08:00AM Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent
Jun 6, 2016 08:00AM KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
Jun 6, 2016 06:35AM Merck (MRK) Announces Presentation of New KEYTRUDA Data in NSCLC
View More Recent Stories View Older Stories